0.5389
price up icon2.12%   0.0112
pre-market  Vorhandelsmarkt:  .55   0.0111   +2.06%
loading
Schlusskurs vom Vortag:
$0.5277
Offen:
$0.5261
24-Stunden-Volumen:
126.92K
Relative Volume:
0.56
Marktkapitalisierung:
$55.52M
Einnahmen:
$1.29M
Nettoeinkommen (Verlust:
$-29.87M
KGV:
-1.4969
EPS:
-0.36
Netto-Cashflow:
$-14.70M
1W Leistung:
+11.23%
1M Leistung:
+13.45%
6M Leistung:
-8.92%
1J Leistung:
-25.88%
1-Tages-Spanne:
Value
$0.512
$0.5699
1-Wochen-Bereich:
Value
$0.475
$0.57
52-Wochen-Spanne:
Value
$0.3951
$0.90

VolitionRX Ltd Stock (VNRX) Company Profile

Name
Firmenname
VolitionRX Ltd
Name
Telefon
646 650 1351
Name
Adresse
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Name
Mitarbeiter
37
Name
Twitter
@VolitionRx
Name
Nächster Verdiensttermin
2025-03-31
Name
Neueste SEC-Einreichungen
Name
VNRX's Discussions on Twitter

Vergleichen Sie VNRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
VNRX
VolitionRX Ltd
0.5389 49.91M 1.29M -29.87M -14.70M -0.36
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
399.93 152.34B 42.90B 6.52B 6.72B 17.05
Diagnostics & Research icon
DHR
Danaher Corp
192.06 135.39B 23.82B 3.77B 4.90B 5.15
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
525.83 41.54B 3.93B 894.97M 837.70M 10.82
Diagnostics & Research icon
A
Agilent Technologies Inc
112.76 31.61B 6.63B 1.17B 1.19B 4.05
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
142.78 24.31B 15.50B 1.33B 2.16B 7.34

VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-08 Eingeleitet H.C. Wainwright Buy
2023-02-01 Herabstufung The Benchmark Company Buy → Hold
2022-02-17 Fortgesetzt Cantor Fitzgerald Overweight
2021-03-10 Eingeleitet Cantor Fitzgerald Overweight
2018-05-16 Eingeleitet Maxim Group Buy
2018-05-14 Bestätigt The Benchmark Company Buy
2016-09-07 Bestätigt Rodman & Renshaw Buy
2016-02-01 Eingeleitet Rodman & Renshaw Buy
Alle ansehen

VolitionRX Ltd Aktie (VNRX) Neueste Nachrichten

pulisher
May 27, 2025

VNRX: Management's key financial goal for 2025 is to be cash neutral on a full year basis. - Research Tree

May 27, 2025
pulisher
May 27, 2025

VNRX: Management’s key financial goal for 2025 is to be cash neutral on a full year basis. Four operational milestones have been achieved thus far in 2025. Primary operational goal is to enter into multiple licensing agreements for human diagnostic applicati - Yahoo Finance

May 27, 2025
pulisher
May 20, 2025

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 20, 2025
pulisher
May 19, 2025

VolitionRX Ltd. Earnings Call Reveals Promising Growth - TipRanks

May 19, 2025
pulisher
May 19, 2025

VolitionRX shares hold as Benchmark maintains rating - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

VNRX stock touches 52-week low at $0.42 amid market challenges - Investing.com Canada

May 19, 2025
pulisher
May 19, 2025

VolitionRX shares hold as Benchmark maintains rating By Investing.com - Investing.com India

May 19, 2025
pulisher
May 19, 2025

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats - Yahoo Finance

May 19, 2025
pulisher
May 19, 2025

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats By Investing.com - Investing.com Canada

May 19, 2025
pulisher
May 17, 2025

VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Milestones - Yahoo Finance

May 17, 2025
pulisher
May 17, 2025

VolitionRx Reports Strong Q1 2025 Performance - TipRanks

May 17, 2025
pulisher
May 16, 2025

VolitionRX (VNRX) Sees Revenue Growth and Cost Reduction in Q1 2 - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast By Investing.com - Investing.com Nigeria

May 16, 2025
pulisher
May 16, 2025

Transcript : VolitionRx Limited, Q1 2025 Earnings Call, May 16, 2025 - marketscreener.com

May 16, 2025
pulisher
May 16, 2025

Earnings call transcript: VolitionRx misses Q1 2025 earnings forecast - Investing.com

May 16, 2025
pulisher
May 16, 2025

Volitionrx Ltd earnings missed by $0.02, revenue fell short of estimates - Investing.com UK

May 16, 2025
pulisher
May 16, 2025

VolitionRX: Q1 Earnings Snapshot - CT Insider

May 16, 2025
pulisher
May 16, 2025

VolitionRx Q1 2025 Earnings Call Transcript - MarketBeat

May 16, 2025
pulisher
May 15, 2025

Volitionrx Ltd earnings missed by $0.03, revenue fell short of estimates - Investing.com South Africa

May 15, 2025
pulisher
May 15, 2025

VolitionRx reports Q1 revenue $0.25M, consensus $1.08M - TipRanks

May 15, 2025
pulisher
May 15, 2025

Volition (VNRX) Targets Diagnostic Market Expansion with Nu.Q Platform | VNRX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

VolitionRX Ltd Reports Q1 2025 Revenue of $0.25 Million, Missing - GuruFocus

May 15, 2025
pulisher
May 15, 2025

VolitionRX Ltd (VNRX) Q1 2025 Earnings Report Preview: What To Look For - GuruFocus

May 15, 2025
pulisher
May 12, 2025

VolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business Update - Yahoo Finance

May 12, 2025
pulisher
May 10, 2025

VolitionRx (VNRX) Expected to Announce Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 09, 2025

VolitionRx Limited Announces Closing of $16.5 Million Underwritten Public Offering of Common Stock - Barchart.com

May 09, 2025
pulisher
May 07, 2025

VolitionRx Updates Progress Of Nu.Q NETs Test Adoption - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

VolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoption - Yahoo Finance

May 07, 2025
pulisher
May 07, 2025

StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World

May 07, 2025
pulisher
Apr 29, 2025

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets - Yahoo Finance

Apr 29, 2025
pulisher
Apr 25, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 25, 2025
pulisher
Apr 23, 2025

VolitionRx enters new sales agreement, terminates old one - Investing.com Australia

Apr 23, 2025
pulisher
Apr 22, 2025

VolitionRx enters new sales agreement, terminates old one By Investing.com - Investing.com South Africa

Apr 22, 2025
pulisher
Apr 18, 2025

VolitionRX Ltd (AMEX: VNRX): An Enticing Stock To Watch - stocksregister.com

Apr 18, 2025
pulisher
Apr 18, 2025

Insider Buying: Reynolds Cameron John, VolitionRX Ltd [VNRX] President and CEO invested 181,818 shares - knoxdaily.com

Apr 18, 2025
pulisher
Apr 14, 2025

VolitionRx (NYSE:VNRX) Now Covered by StockNews.com - The AM Reporter

Apr 14, 2025
pulisher
Apr 11, 2025

H.C. Wainwright maintains buy on VolitionRX with $2.50 target By Investing.com - Investing.com South Africa

Apr 11, 2025
pulisher
Apr 10, 2025

VolitionRx (NYSE:VNRX) Coverage Initiated at HC Wainwright - The AM Reporter

Apr 10, 2025
pulisher
Apr 10, 2025

What is HC Wainwright’s Estimate for VolitionRx Q1 Earnings? - Defense World

Apr 10, 2025
pulisher
Apr 10, 2025

VolitionRX stock holds as Benchmark maintains rating - Investing.com Australia

Apr 10, 2025
pulisher
Apr 09, 2025

VolitionRx (NYSE:VNRX) Now Covered by Analysts at HC Wainwright - Defense World

Apr 09, 2025
pulisher
Apr 08, 2025

VolitionRX stock holds as Benchmark maintains rating By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

This Weyerhaeuser Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga

Apr 08, 2025
pulisher
Apr 08, 2025

HC Wainwright Initiates VolitionRx With Buy Rating, $2.50 Price Target - marketscreener.com

Apr 08, 2025
pulisher
Apr 05, 2025

VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com - Defense World

Apr 05, 2025
pulisher
Apr 04, 2025

VolitionRx Moves to Register Warrant Shares on New Form By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

VolitionRx Moves to Register Warrant Shares on New Form - Investing.com

Apr 04, 2025

Finanzdaten der VolitionRX Ltd-Aktie (VNRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
diagnostics_research DGX
$173.59
price down icon 0.46%
diagnostics_research WAT
$349.39
price up icon 1.66%
diagnostics_research LH
$250.51
price up icon 1.07%
$160.15
price down icon 0.34%
diagnostics_research MTD
$1,166.46
price up icon 2.22%
diagnostics_research IQV
$142.78
price up icon 2.65%
Kapitalisierung:     |  Volumen (24h):